Published in Clin Exp Immunol on May 01, 1981
Dynamics of mononuclear phagocyte system Fc receptor function in systemic lupus erythematosus. Relation to disease activity and circulating immune complexes. Clin Exp Immunol (1983) 1.04
Reactivity of low molecular weight material in cellular immune complex assays. Clin Exp Immunol (1983) 0.90
Serum immune complexes in systemic sclerosis: relationship with precipitating nuclear antibodies. Ann Rheum Dis (1985) 0.79
Evaluation of anti-C1q capture assay for detecting circulating immune complexes and comparison with polyethylene glycol-immunoglobulin G, C1q-binding, and Raji cell methods. J Clin Microbiol (1987) 0.75
Fluorescent anti-immunoglobulin G assay of circulating immune complexes extracted with polyethylene glycol. J Clin Microbiol (1986) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
A method of trace iodination of proteins for immunologic studies. Int Arch Allergy Appl Immunol (1966) 43.66
A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE. J Clin Pathol (1965) 8.64
The Raji cell radioimmune assay for detecting immune complexes in human sera. J Clin Invest (1976) 8.06
Precipitin reactions of the C1q component of complement with aggregated gamma-globulin and immune complexes in gel diffusion. Immunology (1970) 6.89
Profiles of antinuclear antibodies in systemic rheumatic diseases. Ann Intern Med (1975) 5.00
Analyses of lymphocytes from patients with rheumatoid arthritis and systemic lupus erythematosus. Occurrence of interfering cold-reactive antilymphocyte antibodies. J Clin Invest (1974) 3.24
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Nature of cold-reactive antibodies to lymphocyte surface determinants in systemic lupus erythematosus. Arthritis Rheum (1975) 2.65
Binding of soluble immune complexes to human lymphoblastoid cells. I. Characterization of receptors for IgG Fc and complement and description of the binding mechanism. J Exp Med (1974) 2.22
Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature (1978) 1.91
Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis (1975) 1.67
Detection of circulating immune complexes in patients with glomerulonephritis. Kidney Int (1977) 1.66
Antibody penetration into living cells. II. Anti-ribonucleoprotein IgG penetrates into Tgamma lymphocytes causing their deletion and the abrogation of suppressor function. J Immunol (1979) 1.63
Isolation of circulating immune complexes using Raji cells. Separation of antigens from immune complexes and production of antiserum. J Clin Invest (1978) 1.28
Circulating immune complex assays in patients with lupus and membranous glomerulonephritis. Clin Immunol Immunopathol (1979) 1.02
Synthesis of cytoplasmic membrane-associated DNA in lymphocyte nucleus. Nat New Biol (1971) 0.97
Is autoimmunity a common denominator in immune complex diseases? Lancet (1980) 0.90
Circulating immune complexes in mixed connective tissue disease. Arthritis Rheum (1979) 0.84
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 10.22
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Rheumatoid arthritis. Cell (1996) 6.01
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
A micro-method for peripheral leucocyte migration in tuberculin sensitivity. J Clin Pathol (1971) 3.45
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res (2000) 2.37
TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34
Measurement of DNA antibodies by double antibody precipitation. Ann Rheum Dis (1973) 2.21
Kaposi's sarcoma in two patients following low-dose corticosteroid treatment for rheumatological disease. Rheumatology (Oxford) (2000) 2.10
The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. Q J Med (1979) 2.07
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03
The clinical significance of mediators of cellular immunity. Clin Allergy (1971) 2.03
Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. Br Med J (1978) 2.01
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01
A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum (1985) 1.99
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum (1998) 1.79
Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus. Arthritis Rheum (1999) 1.76
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum (2001) 1.74
Purification and characterization of the Sjögren's syndrome A and B antigens. Clin Exp Immunol (1983) 1.73
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.72
Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis (2008) 1.71
Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis (1975) 1.67
HLA and rheumatoid arthritis: a combined analysis of 440 British patients. Ann Rheum Dis (1986) 1.66
Evidence of Chlamydia trachomatis infection in sexually acquired reactive arthritis. Ann Rheum Dis (1980) 1.65
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol (1992) 1.59
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum (2004) 1.56
Murine lupus monoclonal antibodies define five epitopes on two different Sm polypeptides. Immunology (1986) 1.54
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol (1997) 1.53
Serological and immunogenetic markers of extraglandular primary Sjögren's syndrome. Br J Rheumatol (1993) 1.53
Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum (1992) 1.53
DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol (1997) 1.52
Lymphocyte mitogenic factor in man. Nature (1969) 1.51
Titers of antibodies to RANA in rheumatoid arthritis and normal sera. Relationship to Epstein-Barr virus infection. Arthritis Rheum (1981) 1.49
Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum (2000) 1.49
Quantitation and detection of isotypes of anti-SS-B antibodies by ELISA and Farr assays using affinity purified antigens. An approach to the investigation of Sjögren's syndrome and systemic lupus erythematosus. Arthritis Rheum (1983) 1.48
Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw (1996) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Antibodies to extractable nuclear antigens in rheumatoid arthritis: relationship to vasculitis and circulating immune complexes. Clin Exp Immunol (1980) 1.47
Monoclonal antibodies to the Sjögren's syndrome associated antigen SS-B (La). J Immunol Methods (1985) 1.46
Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol (1997) 1.46
Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol (1992) 1.44
Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci U S A (1994) 1.42
Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis (1984) 1.41
Standardization of the leucocyte migration test. Int Arch Allergy Appl Immunol (1973) 1.39
The association of cryoglobulinaemia with nodules, vasculitis and fibrosing alveolitis in rheumatoid arthritis and their relationship to serum C1q binding activity and rheumatoid factor. Clin Exp Immunol (1979) 1.39
Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis (1990) 1.38
Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum (2002) 1.38
Virus infection induces redistribution and membrane localization of the nuclear antigen La (SS-B): a possible mechanism for autoimmunity. Clin Exp Immunol (1989) 1.36
Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol (1999) 1.35
Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun (1989) 1.33
T cells expressing gamma delta chain receptors in rheumatoid arthritis. J Autoimmun (1988) 1.32
Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis (1989) 1.31
The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.29
The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. Br J Rheumatol (1992) 1.27
Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol (2000) 1.27
Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol (1998) 1.27
Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol (1997) 1.26
The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun (2001) 1.26
A novel exogenous retrovirus sequence identified in humans. J Virol (1997) 1.26
High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum (1995) 1.26
Coordinate expansion of 'fetal type' lymphocytes (TCR gamma delta+T and CD5+B) in rheumatoid arthritis and primary Sjögren's syndrome. Clin Exp Immunol (1989) 1.25
Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol (1997) 1.23
Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. J Immunol Methods (1982) 1.23
Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis (1988) 1.23
Separation of two molecular species of the Sm antigen by affinity chromatography with murine monoclonal and human anti-nuclear autoantibodies. Clin Exp Immunol (1983) 1.22
HLA antigen associations with extra-articular rheumatoid arthritis. Tissue Antigens (1984) 1.22